Produktinformation
AM281 is a cannabinoid receptor antagonist that binds to the CB1 cannabinoid receptor and blocks the effect of cannabinoids. AM281 has been shown to reduce the number of bowel disease-related symptoms in mice by reversing the up-regulation of toll-like receptors (TLRs) in the colon. AM281 also reduces inflammation and injury by inhibiting DPP-IV, an enzyme that destroys insulin, which leads to a synergistic effect on neurons in rats. AM281 has been shown to have a synergistic effect with DPP-IV inhibitors, leading to an increase in neuronal activity and improved memory retention. It is used for brain injury research, as it blocks the effects of cannabinoids on hippocampal neurons.
Chemische Eigenschaften
Technische Anfrage zu: AM 281
Bitte verwenden Sie stattdessen den Warenkorb, um ein Angebot oder eine Bestellung anzufordern
